Who are DWC202404, DWC202314's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DWC202405, DWC202314, Botox infiltration, Abobotulinum toxin A, BOTOX®/VISTABEL®, Onabotulinum Toxin A, Incobotulinumtoxin A Injectable Product.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dwc202404-dwc202314.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

DWC202404, DWC202314 — Competitive Intelligence Brief

DWC202404, DWC202314 (DWC202404, DWC202314) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Botulinum toxin. Area: Neurology.

phase 3 Botulinum toxin Acetylcholine release inhibitor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

DWC202404, DWC202314 (DWC202404, DWC202314) — Daewoong Pharmaceutical Co. LTD.. DWC202404 and DWC202314 are botulinum toxin type A serotypes used for the treatment of various conditions.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
DWC202404, DWC202314 TARGET	DWC202404, DWC202314	Daewoong Pharmaceutical Co. LTD.	phase 3	Botulinum toxin	Acetylcholine release inhibitor
DWC202405, DWC202314	DWC202405, DWC202314	Daewoong Pharmaceutical Co. LTD.	phase 3	Botulinum toxin	Acetylcholine release inhibitor
Botox infiltration	Botox infiltration	University Rovira i Virgili	marketed	Neurotoxin; botulinum toxin type A	SNARE complex (synaptosome-associated protein); acetylcholine release machinery
Abobotulinum toxin A	Abobotulinum toxin A	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
BOTOX®/VISTABEL®	BOTOX®/VISTABEL®	AbbVie	marketed	Botulinum toxin	SNARE complex (synaptosome-associated protein)
Onabotulinum Toxin A	Onabotulinum Toxin A	Walter Reed National Military Medical Center	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
Incobotulinumtoxin A Injectable Product	Incobotulinumtoxin A Injectable Product	University of Utah	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Botulinum toxin class)

Galderma R&D · 2 drugs in this class
Hexsel Dermatology Clinic · 2 drugs in this class
Seoul National University Hospital · 2 drugs in this class
University of Utah · 2 drugs in this class
Daewoong Pharmaceutical Co. LTD. · 2 drugs in this class
EuBiologics Co.,Ltd · 1 drug in this class
Allergan · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Beth Israel Deaconess Medical Center · 1 drug in this class
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DWC202404, DWC202314 — Competitive Intelligence Brief. https://druglandscape.com/ci/dwc202404-dwc202314. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab